PDS BIOTECHNOLOGY CORPORATION PDSB 深 滬
等待開盤 11-26 09:30:00 美东时间
0.7456
-0.011
-1.52%
華盛通- 最 高0.7601
- 今 開0.7524
- 成交量 23.54万股
- 最 低 0.7257
- 昨 收 0.7571
- 總市值 3408.14万
- 52周最高 2.2818
- 市盈率 靜 --
- 換手率 0.51%
- 52周最低 0.7257
- 委 比 -93.33%
- 總股本 4571.00万
- 歷史最高 17.85
- 量 比 0.50
- 振 幅 4.54%
- 歷史最低 0.615
- 每 手 1
- 風險率 0.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
今天 10:07
B. Riley Securities Maintains Buy on PDS Biotechnology, Lowers Price Target to $3
B. Riley Securities analyst Kalpit Patel maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and lowers the price target from $5 to $3.
今天 02:14
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
PDS Biotechnology Q3 EPS $(0.19) Beats $(0.22) Estimate
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 34.48 percent increase over losses of $(0.29) per share from
11-13 20:31
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
11-13 19:11
A Look Ahead: PDS Biotechnology's Earnings Forecast
PDS Biotechnology (NASDAQ:PDSB) is preparing to release its quarterly earnings ...
11-13 01:03
PDS Biotechnology Announces $5.3M Registered Direct Offering Of 5.8M Shares With Warrants At A Combined Price Of $0.91
PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that it has
11-12 04:35
PDS Biotechnology Presents Clinical, Translational Data On Investigational Hpv16-Targeted Immunotherapy Pds0101 And Its Novel, Investigational Immunocytokine Pds01ADC
PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced positive clinical
11-10 21:34
PDS Biotechnology Seeks FDA Meeting for PDS0101 Approval
PDS Biotechnology ( ($PDSB) ) has provided an update. On October 29, 2025, PDS ...
10-29 21:18
PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer
PDS Biotechnology Corporation seeks to accelerate approval of PDS0101 for HPV16-positive head and neck cancer patients. The company requested an FDA meeting to discuss an expedited pathway, proposing to amend the VERSATILE-003 trial to add progression-free survival (PFS) as an earlier primary endpoint alongside median overall survival (mOS), based on VERSATILE-002 trial results showing a robust mPFS of 6.3 months and mOS of 39.3 months. The trial...
10-29 12:37
